Buyback yield (TTM)
2.59%
Shareholder yield (TTM)
2.59%
5Y share count change
-7.0%
Buyback spend (TTM)
$1.17B
Cumulative buybacks
$7.97B
Key takeaways
- IDEXX Laboratories (IDXX) repurchased about $1.17B of stock over the trailing twelve months.
- Diluted share count is down 7.0% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 12.98× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +46.1% per year over the latest 5-year window.
- TTM repurchases used about 108% of free cash flow remaining after dividends.
Dividend & buyback yield over time for IDEXX Laboratories (IDXX)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for IDEXX Laboratories (IDXX)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for IDEXX Laboratories (IDXX)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for IDEXX Laboratories (IDXX)
Latest: $1.22B
Overview
The 2025 reading of IDEXX Laboratories (IDXX) buyback spend is $1.22B – surged 45.4% year-over-year.
IDEXX Laboratories buyback spend has grown for 2 consecutive years, with a +46.1% compound annual growth rate over 2020–2025 (5 years).
The highest annual buyback spend of $1.22B was reported in 2025. The lowest in the available history was $0.00 in 1991.
IDEXX Laboratories Buyback Spend 2025: $1.22B
IDEXX Laboratories buyback spend in 2025 was $1.22B, surged 45.4% from 2024. This figure represents the highest annual value in the available history.
IDEXX Laboratories Buyback Spend 2024: $837.03M
2024's buyback spend for IDEXX Laboratories came in at $837.03M, surged 1063.8% from 2023.
IDEXX Laboratories Buyback Spend 2023: $71.92M
IDEXX Laboratories posted buyback spend of $71.92M in 2023, plunged 91.2% below 2022.
IDEXX Laboratories Buyback Spend 2022: $819.71M
In 2022, IDEXX Laboratories reported buyback spend of $819.71M, grew 9.8% from 2021.
IDEXX Laboratories Buyback Spend 2021: $746.78M
IDEXX Laboratories buyback spend in 2021 was $746.78M.
See more financial history for IDEXX Laboratories (IDXX).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $1.22B | $0.00 | $1.22B | 2.25% | 0.08B | -3.1% | |
| 2024 | $837.03M | $60.30M | $776.74M | 2.47% | 0.08B | -0.9% | |
| 2023 | $71.92M | $59.74M | $12.18M | 0.16% | 0.08B | -0.7% | |
| 2022 | $819.71M | $49.77M | $769.94M | 2.42% | 0.08B | -2.3% | |
| 2021 | $746.78M | $37.76M | $709.02M | 1.34% | 0.09B | -0.2% | |
| 2020 | $182.81M | $30.95M | $151.86M | 0.43% | 0.09B | -0.9% | |
| 2019 | $301.66M | $39.28M | $262.38M | 1.35% | 0.09B | -1.0% | |
| 2018 | $369.32M | $25.16M | $344.16M | 2.30% | 0.09B | -1.2% | |
| 2017 | $290.64M | $23.52M | $267.12M | 2.13% | 0.09B | -1.4% | |
| 2016 | $304.09M | $19.89M | $284.19M | 2.90% | 0.09B | -3.0% | |
| 2015 | $401.98M | $19.88M | $382.10M | 6.07% | 0.09B | -7.7% | |
| 2014 | $618.16M | $18.10M | $600.06M | 8.73% | 0.10B | -6.0% | |
| 2013 | $367.76M | $16.54M | $351.22M | 6.65% | 0.11B | -3.9% | |
| 2012 | $132.27M | $15.95M | $116.32M | 2.60% | 0.11B | -3.5% | |
| 2011 | $255.50M | $15.50M | $240.01M | 6.01% | 0.12B | -2.3% | |
| 2010 | $143.09M | $13.26M | $129.83M | 3.60% | 0.12B | -1.9% | |
| 2009 | $83.10M | $11.62M | $71.48M | 2.68% | 0.12B | -2.5% | |
| 2008 | $132.34M | $10.50M | $121.84M | 6.20% | 0.12B | -3.4% | |
| 2007 | $118.39M | $8.78M | $109.61M | 3.32% | 0.13B | -2.2% | |
| 2006 | $105.71M | $10.84M | $94.87M | 4.28% | 0.13B | -3.2% | |
| 2005 | $123.77M | $135.00K | $123.63M | 5.41% | 0.14B | -4.9% | |
| 2004 | $129.19M | $135.00K | $129.06M | 7.18% | 0.14B | -0.4% | |
| 2003 | $35.82M | $138.00K | $35.68M | 2.23% | 0.14B | +2.5% | |
| 2002 | $29.83M | $0.00 | $29.83M | 2.71% | 0.14B | +1.2% | |
| 2001 | $12.99M | $0.00 | $12.99M | 1.34% | 0.14B | -4.0% | |
| 2000 | $70.26M | $0.00 | $70.26M | — | 0.14B | -9.2% | |
| 1999 | $64.20M | $0.00 | $64.20M | — | 0.16B | +4.6% | |
| 1998 | $0.00 | $0.00 | $0.00 | — | 0.15B | +0.9% | |
| 1997 | $0.00 | $0.00 | $0.00 | — | 0.15B | -4.1% | |
| 1996 | $0.00 | $0.00 | $0.00 | — | 0.16B | — | |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1992 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — |
- 2025$1.22B
- 2024$837.03M
- 2023$71.92M
- 2022$819.71M
- 2021$746.78M
- 2020$182.81M
- 2019$301.66M
- 2018$369.32M
- 2017$290.64M
- 2016$304.09M
- 2015$401.98M
- 2014$618.16M
- 2013$367.76M
- 2012$132.27M
- 2011$255.50M
- 2010$143.09M
- 2009$83.10M
- 2008$132.34M
- 2007$118.39M
- 2006$105.71M
- 2005$123.77M
- 2004$129.19M
- 2003$35.82M
- 2002$29.83M
- 2001$12.99M
- 2000$70.26M
- 1999$64.20M
- 1998$0.00
- 1997$0.00
- 1996$0.00
- 1995$0.00
- 1994$0.00
- 1993$0.00
- 1992$0.00
- 1991$0.00
Buybacks vs stock-based compensation for IDEXX Laboratories (IDXX)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 12.98×.
Buybacks vs dividends (share of cash returned) for IDEXX Laboratories (IDXX)
How IDEXX Laboratories splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as IDEXX Laboratories, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $1.08B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation